Teva Q309 Sales Up

Teva, Israel's largest generic drugmaker, has release its Q309 financial results, announcing a 22% increase in net sales from Q308, to US$3.55bn. BMI believes that the results indicate that the firm is faring well in difficult economic conditions and has gained considerably since the Barr acquisition in 2008.

To read the full article, please sign in or take a free trial.